Eicosapentaenoic acid - SLA Pharma

Drug Profile

Eicosapentaenoic acid - SLA Pharma

Alternative Names: ALFA

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SLA Pharma
  • Developer SLA Pharma; University of Bologna
  • Class Antihyperlipidaemics; Eicosanoids; Omega 3 fatty acids; Small molecules
  • Mechanism of Action Arachidonic acid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Familial adenomatous polyposis
  • Phase I/II Colorectal cancer; Ulcerative colitis
  • No development reported Crohn's disease; Intestinal polyps

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Crohn's-disease in Italy (PO, Capsule)
  • 17 Jun 2015 Clinical development for Familial adenomatous polyposis is ongoing in the United Kingdom
  • 17 Jun 2015 No recent reports of development identified - Phase-II for Colorectal cancer (Late-stage disease, Metastatic disease, Neoadjuvant therapy) in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top